CN-121987650-A - Application of ginsenoside Ro in preparing medicine for treating cerebral ischemia reperfusion injury

Abstract

The invention discloses application of ginsenoside Ro in preparing a medicament for treating cerebral ischemia reperfusion injury. The invention discovers that ginsenoside Ro can reduce the cerebral infarction volume of a model mouse, improve pathological damage of brain tissues and increase cerebral blood flow on the ischemia side by preparing a cerebral middle artery occlusion/reperfusion (Middle cerebral artery occlusion/reperfusion, MCAO/R) mouse model. Meanwhile, ginsenoside Ro up-regulates the expression of brain tissue tight junction proteins ZO-1 and Occludin, inhibits the expression of matrix metalloproteinase MMP-9/2, reduces leakage of Evans blue, and improves blood brain barrier (Blood brain barrier, BBB) dysfunction. In addition, by preparing an oxygen glucose deprivation/reperfusion (OGD/R) induced mouse brain microvascular endothelial (brain endothelial cell line, bEnd.3) cell model, ginsenoside Ro is found to improve OGD/R induced bEnd.3 cell barrier function damage, and the novel medical application of ginsenoside Ro in treating ischemic cerebral apoplexy is proved to have wide application prospect.

Inventors

• KOU JUNPING
• GONG SHUAISHUAI
• XU YUANHAO
• LI FANG
• ZHANG YUANYUAN

Assignees

• 中国药科大学

Dates

Publication Date

20260508

Application Date

20260327

Claims (8)

1. 1. Application of ginsenoside Ro in preparing medicine for treating cerebral ischemia reperfusion injury is provided.
2. 2. Application of ginsenoside Ro in preparing medicine for preventing cerebral ischemia reperfusion injury is provided.
3. 3. A pharmaceutical composition for treating cerebral ischemia reperfusion injury, comprising ginsenoside Ro.
4. 4. A pharmaceutical composition according to claim 3, comprising a pharmaceutically acceptable carrier, in the form of an injection, tablet or capsule.
5. 5. Use of ginsenoside Ro in preparing medicine for up-regulating expression of zonulin ZO-1, occludin.
6. 6. Application of ginsenoside Ro in preparing medicine for improving cerebral infarction, nerve dysfunction, brain injury or blood brain barrier dysfunction is provided.
7. 7. Use of ginsenoside Ro in preparing medicine for improving OGD/R-induced bEnd.3 cell barrier function injury is provided.
8. 8. Application of ginsenoside Ro in preparing medicine for inhibiting MMP-9 and MMP-2 protein expression is provided.

Description

Application of ginsenoside Ro in preparing medicine for treating cerebral ischemia reperfusion injury Technical Field The invention relates to the technical field of biological medicines, in particular to application of ginsenoside Ro in preparing a medicine for treating cerebral ischemia reperfusion injury. Background Stroke (Stroke) is a type of acute cerebrovascular disease that severely jeopardizes human health and is the second leading cause of global disability and death. Ischemic stroke is the main type of stroke, accounting for 87% of all strokes. Venous thrombolysis is one of the most effective measures for recovering cerebral blood flow of acute ischemic cerebral apoplexy patients at present, and the general medicine is a recombinant tissue type plasminogen activator (alteplase), but the medicine treats window stenosis (less than or equal to 4.5 h) and has potential risk of inducing cerebral hemorrhage. Thrombolytic therapy restores blood supply to rescue ischemic brain tissue, but reperfusion further exacerbates the extent and scope of brain injury, known as cerebral ischemia reperfusion injury. Acute ischemic stroke caused by large vessel occlusion can be treated by mechanical thrombectomy within 24 hours after the onset of stroke symptoms. Mechanical thrombectomy may improve the functional outcome of the patient compared to alteplase. However, mechanical thrombectomy requires specialized equipment and is performed by a physician trained in endovascular surgery, requiring extremely high medical resources. Therefore, the pathological links and action mechanisms in the cerebral ischemia reperfusion injury process are deeply discussed, and the pathological links and action mechanisms are subjected to pharmaceutical intervention, so that the method has important significance in improving reperfusion injury caused by cerebral blood flow recovery. Ischemic stroke has a complex pathological mechanism, and one of its prominent pathological features is BBB dysfunction. The BBB exists at the blood and brain interface and is a biological barrier that maintains the central nervous system and precisely regulates the homeostasis of the brain microenvironment. Endothelial cells are one of the most important components of the BBB and react to potentially harmful chemicals released by the ischemic, hypoxic and vascular systems. Endothelial cells undergo cytoskeletal rearrangement, increased transcellular transport and altered tight junctions following ischemia, exacerbating BBB injury and secondary brain injury. Therefore, the key links and molecular mechanisms involved in the damage of the brain microvascular endothelial barrier are explored, and the target for preventing and treating the BBB injury of the ischemic stroke is found, so that the method has important significance in the research and development of medicines for preventing and treating the ischemic stroke. The Ginseng radix is root of Ginseng radix of Araliaceae. Has effects of warming, slightly bitter, slightly warm, invigorating spleen and lung channel, invigorating primordial qi, restoring pulse beat, relieving depletion, invigorating spleen, benefiting lung, promoting salivation, nourishing blood, tranquilizing mind, and improving intelligence. Ginsenoside Ro (Ginsenoside Ro) is a natural substance with biological activity separated from radix Ginseng, and has anti-inflammatory, antioxidant, antithrombotic, antitumor, and blood lipid reducing effects. However, the application of ginsenoside Ro in ischemic stroke has not been reported at present. Disclosure of Invention The invention aims to provide an application of ginsenoside Ro in preparing a medicine for treating cerebral ischemia reperfusion injury. In order to achieve the aim of the invention, the technical scheme of the application of the ginsenoside Ro provided by the invention is as follows: the invention provides application of ginsenoside Ro in preparing a medicament for treating cerebral ischemia reperfusion injury. The invention provides application of ginsenoside Ro in preparing a medicament for preventing cerebral ischemia reperfusion injury. The invention provides a pharmaceutical composition for treating cerebral ischemia reperfusion injury, which comprises ginsenoside Ro. Preferably, the pharmaceutical composition comprises a pharmaceutically acceptable carrier, and the preparation form is injection, tablet or capsule. The invention provides application of ginsenoside Ro in preparing medicines for up-regulating expression of tight junction proteins ZO-1 and Occludin. The invention provides application of ginsenoside Ro in preparing medicines for improving cerebral infarction, nerve dysfunction and Blood Brain Barrier (BBB) dysfunction. The invention provides application of ginsenoside Ro in preparing a medicine for treating OGD/R-induced bEnd.3 cell barrier function injury. The invention provides application of ginsenoside Ro in preparing medicines for inhibiting MMP-9 and MMP